Standout Papers

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer 2015 2026 2018 2022 1.8k
  1. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (2015)
    Christopher J. Sweeney, Yu‐Hui Chen et al. New England Journal of Medicine
  2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial (2018)
    Christos E. Kyriakopoulos, Yu‐Hui Chen et al. Journal of Clinical Oncology
  3. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study (2019)
    Funda Meric‐Bernstam, Herbert I. Hurwitz et al. The Lancet Oncology
  4. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study (2018)
    John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology
  5. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer (2017)
    Wanling Xie, Meredith M. Regan et al. Journal of Clinical Oncology
  6. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study (2021)
    Milind Javle, Mitesh J. Borad et al. The Lancet Oncology
  7. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial (2022)
    Thomas Powles, Kobe Yuen et al. Nature Medicine

Immediate Impact

11 by Nobel laureates 6 from Science/Nature 87 standout
Sub-graph 1 of 19

Citing Papers

Prostate Cancer
2025 Standout
Colorectal cancer
2024 Standout
23 intermediate papers

Works of Christopher J. Sweeney being referenced

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
2019 Standout
Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups
2014
and 20 more

Author Peers

Author Last Decade Papers Cites
Christopher J. Sweeney 8524 5130 4098 4376 402 15.6k
E. David Crawford 11102 3948 3111 3928 275 17.0k
Kurt Miller 8902 2897 3462 4529 350 14.4k
Primo N. Lara 8262 6857 3422 5908 448 15.9k
Tomasz M. Beer 10570 5989 4162 4244 402 17.4k
Christopher J. Logothetis 9469 7820 3574 6778 448 20.4k
Malcolm D. Mason 7386 3663 3991 6396 239 17.6k
Joel Picus 8932 9106 4488 4168 223 17.7k
Yoshitaka Fujii 8943 8242 3917 7574 436 19.6k
George Wilding 11923 6748 5214 9776 308 21.9k
Martin Fleisher 4986 4451 3301 3333 240 12.2k

All Works

Loading papers...

Rankless by CCL
2026